Lyell completes LYL273 manufacturing transfer, pushes back Phase 1/2 data timelineSep 10Clinical readoutLyell Immunopharma, Inc.
AstraZeneca posts Phase 3 LOGOS, KALOS asthma results; updates Soliris labelJul 2Weekly roundup, 5 itemsAstraZenecaAZD4045
Sign inSign in